# Trastuzumab

Source: https://onco.cc/drugs/trastuzumab/  
OnCo record `trastuzumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The first targeted antibody for a solid tumour (1998), which turned HER2-positive breast cancer from the worst subtype into one of the most treatable.

## Summary

Trastuzumab is a humanised IgG1 antibody that binds domain IV of HER2, blocking receptor signalling and recruiting immune cells through ADCC. It was the first targeted antibody for a solid tumour, approved for HER2-positive metastatic breast cancer in 1998, as adjuvant therapy in 2006 (HERA, NSABP B-31/N9831, about a 37% reduction in death) and for HER2-positive gastric cancer in 2010. Dual blockade with pertuzumab (CLEOPATRA, APHINITY) and the subcutaneous Phesgo built on it, and it is the antibody backbone of the conjugates T-DM1 and T-DXd. Adjuvant treatment lasts 1 year, and cardiomyopathy requires LVEF monitoring. Biosimilars since 2017 have cut cost worldwide, and whether shorter adjuvant courses are safe for lower-risk patients remains debated. For a newcomer: the drug that turned the worst breast cancer subtype into one of the most treatable.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-04
- Also known as: Trastuzumab and Hyaluronidase-oysk; Herceptin Hylecta
- Brand: Herceptin (and biosimilars, Phesgo with pertuzumab)
- Modality: Monoclonal antibody (anti-HER2)
- Mechanism: Humanised IgG1 binding HER2 ECD4; signal inhibition and ADCC.
- Approvals: US 1998: HER2+ metastatic breast cancer; US 2006: Adjuvant HER2+ breast cancer; US 2010: HER2+ gastric cancer
- Dosing: IV infusion (subcutaneous Herceptin Hylecta / Phesgo with pertuzumab available); 8 mg/kg loading then 6 mg/kg every 3 weeks (or 4 then 2 mg/kg weekly); 1 year adjuvant

## Notes

- Colorectal cancer biomarkers: HER2 positivity by the HERACLES criteria, intense membranous staining in more than 50% of cells corresponding to homogeneous amplification, in a RAS wild-type tumour. That is about 5% of RAS wild-type patients, so roughly 20 must be screened to find one (Valtorta 2015, Sartore-Bianchi 2016). The combination with lapatinib gave 8 responses in 27 patients and has since been superseded by tucatinib plus trastuzumab and trastuzumab deruxtecan.
- Biliary tract cancer: with pertuzumab, objective response rate 23% (9 of 39) in previously treated HER2-positive disease in the MyPathway basket (Javle 2021); off-label.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Trastuzumab
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Trastuzumab

## Connected records

- pairings: [Early FDG-PET response → chemotherapy omission (HER2+)](https://onco.cc/pairings/pet-adapted-her2-deescalation/), [HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd](https://onco.cc/pairings/her2-gastric-sequence/), [Tucatinib + trastuzumab + capecitabine for brain metastases](https://onco.cc/pairings/tucatinib-triplet-brain-mets/)
- biomarkers: [HER2 IHC 2+ (equivocal, reflex to ISH)](https://onco.cc/biomarkers/her2-ihc-2-plus/), [HER2 IHC 3+ (HER2-positive by immunohistochemistry)](https://onco.cc/biomarkers/her2-ihc-3-plus/), [HER2 ISH amplified (ERBB2 gene amplification)](https://onco.cc/biomarkers/her2-ish-amplified/), [RAS wild-type (extended KRAS and NRAS testing)](https://onco.cc/biomarkers/ras-wild-type/)
- cancers: [Advanced or recurrent endometrial cancer](https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/), [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Early HER2-positive breast cancer](https://onco.cc/cancers/her2-positive-early-breast-cancer/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-amplified colorectal cancer](https://onco.cc/cancers/her2-amplified-colorectal/), [HER2-low and HER2-ultralow metastatic breast cancer](https://onco.cc/cancers/her2-low-metastatic-breast-cancer/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HER2-positive breast cancer with brain metastases](https://onco.cc/cancers/her2-positive-breast-brain-metastases/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/), [Inflammatory breast cancer](https://onco.cc/cancers/inflammatory-breast-cancer/), [Male breast cancer](https://onco.cc/cancers/male-breast-cancer/), [Mucinous ovarian cancer](https://onco.cc/cancers/mucinous-ovarian-cancer/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [p53-abnormal endometrial cancer, including uterine serous carcinoma](https://onco.cc/cancers/endometrial-p53-abnormal/), [Paget disease of the nipple](https://onco.cc/cancers/paget-disease-of-the-nipple/), [Salivary duct carcinoma](https://onco.cc/cancers/salivary-duct-carcinoma/), [Salivary gland cancers](https://onco.cc/cancers/salivary-gland/)
- technologies: [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/), [Downstream purification (Protein A capture, viral clearance, polishing)](https://onco.cc/technologies/downstream-purification-chromatography/), [Heart function after anthracyclines, trastuzumab and chest radiotherapy](https://onco.cc/technologies/cardiotoxicity-surveillance-recovery/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors](https://onco.cc/technologies/anthracycline-cardioprotection/), [Strain echocardiography (global longitudinal strain)](https://onco.cc/technologies/strain-echocardiography-gls/), [Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud)](https://onco.cc/technologies/transcranial-focused-ultrasound-systems/), [Troponin and natriuretic peptide monitoring during cancer treatment](https://onco.cc/technologies/cardiac-biomarker-monitoring/), [What comes back after treatment, treatment by treatment](https://onco.cc/technologies/rejuv-recovery-matrix/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [Biocon](https://onco.cc/companies/biocon/), [Biocon Biologics](https://onco.cc/companies/biocon-biologics/), [Breast Cancer Trials](https://onco.cc/companies/breast-cancer-trials/), [Breast International Group (BIG)](https://onco.cc/companies/big/), [Halozyme Therapeutics](https://onco.cc/companies/halozyme/), [Nippon Kayaku](https://onco.cc/companies/nippon-kayaku/), [NSABP Foundation](https://onco.cc/companies/nsabp-foundation/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/), [Samsung Bioepis](https://onco.cc/companies/samsung-bioepis/), [SOLTI Cancer Research Group](https://onco.cc/companies/solti/)
- trials: [A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer](https://onco.cc/trials/nct07102381/), [A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer](https://onco.cc/trials/nct06764875/), [A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct06057610/), [A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial](https://onco.cc/trials/nct02320435/), [A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies](https://onco.cc/trials/nct00781612/), [A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o](https://onco.cc/trials/nct06435429/), [A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy](https://onco.cc/trials/nct04873362/), [A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M](https://onco.cc/trials/nct07518173/), [A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea](https://onco.cc/trials/nct06891833/), [A Study of DB-1310 in Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05785741/), [A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.](https://onco.cc/trials/nct07315750/), [A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor](https://onco.cc/trials/nct07140393/), [A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma](https://onco.cc/trials/nct07069712/), [A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer](https://onco.cc/trials/nct05980481/), [A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer](https://onco.cc/trials/nct07679360/), [A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)](https://onco.cc/trials/nct04721977/), [A Study of Tucatinib and Trastuzumab in People With Rectal Cancer](https://onco.cc/trials/nct05672524/), [A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other](https://onco.cc/trials/nct05081609/), [A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer](https://onco.cc/trials/nct07196774/), [A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct07497386/), [APHINITY](https://onco.cc/trials/aphinity/), [APT (adjuvant paclitaxel-trastuzumab)](https://onco.cc/trials/apt-trial/), [ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer](https://onco.cc/trials/nct07007559/), [ATEMPT](https://onco.cc/trials/atempt/), [Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations](https://onco.cc/trials/nct04579380/), [Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit](https://onco.cc/trials/nct06324357/), [Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer](https://onco.cc/trials/nct01275677/), [CLEOPATRA](https://onco.cc/trials/cleopatra/), [Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer](https://onco.cc/trials/nct00016276/), [Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer](https://onco.cc/trials/nct04082364/), [CUPISCO](https://onco.cc/trials/cupisco/), [DETERMINE](https://onco.cc/trials/determine-trial/), [DETERMINE arm 04: trastuzumab with pertuzumab in HER2-amplified or mutated rare cancers](https://onco.cc/trials/determine-arm04/), [Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer](https://onco.cc/trials/nct02003209/), [Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer](https://onco.cc/trials/nct07059338/), [First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)](https://onco.cc/trials/nct05749900/), [GeparSixto](https://onco.cc/trials/geparsixto/), [HER2CLIMB](https://onco.cc/trials/her2climb/), [HER2CLIMB-05](https://onco.cc/trials/her2climb-05/), [HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)](https://onco.cc/trials/hera-b31-n9831/), [HERACLES](https://onco.cc/trials/heracles/), [HERIZON-GEA-01](https://onco.cc/trials/herizon-gea-01/), [Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer](https://onco.cc/trials/nct03803553/), [KATHERINE](https://onco.cc/trials/katherine/), [KEYNOTE-811](https://onco.cc/trials/keynote-811/), [KRISTINE](https://onco.cc/trials/kristine/), [MARGetuximab Or Trastuzumab (MARGOT)](https://onco.cc/trials/nct04425018/), [Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer](https://onco.cc/trials/nct02492711/), [MOUNTAINEER](https://onco.cc/trials/mountaineer/), [MOUNTAINEER-03](https://onco.cc/trials/mountaineer-03/), [MyPathway](https://onco.cc/trials/mypathway/), [NeoSphere](https://onco.cc/trials/neosphere/), [Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging](https://onco.cc/trials/nct07527806/), [PATINA](https://onco.cc/trials/patina/), [PERSEPHONE](https://onco.cc/trials/persephone/), [Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)](https://onco.cc/trials/nct04379596/), [PHERGain](https://onco.cc/trials/phergain/), [Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy](https://onco.cc/trials/nct00769379/), [RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure](https://onco.cc/trials/nct07366840/), [Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06771622/), [Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer](https://onco.cc/trials/nct06245356/), [SAFIR-ABC10](https://onco.cc/trials/safir-abc10/), [Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer](https://onco.cc/trials/nct00615602/), [Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation](https://onco.cc/trials/nct04208178/), [Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies](https://onco.cc/trials/nct05417594/), [Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)](https://onco.cc/trials/nct06686394/), [Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer](https://onco.cc/trials/nct06731478/), [Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct05725200/), [SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer](https://onco.cc/trials/nct03262935/), [TAPUR (Targeted Agent and Profiling Utilization Registry)](https://onco.cc/trials/tapur/), [The Sagittarius Trial](https://onco.cc/trials/nct06490536/), [TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer](https://onco.cc/trials/nct06589830/), [ToGA](https://onco.cc/trials/toga/), [TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer](https://onco.cc/trials/nct07047365/), [TRAIN-2](https://onco.cc/trials/train-2/), [TRAP-BTC](https://onco.cc/trials/trap-btc/), [Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy](https://onco.cc/trials/nct07506057/), [Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients](https://onco.cc/trials/nct07062263/), [Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer](https://onco.cc/trials/nct07129018/), [Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer](https://onco.cc/trials/nct03379428/), [TRIUMPH](https://onco.cc/trials/triumph/), [Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers](https://onco.cc/trials/nct04430738/), [Tucatinib+Trastuzumab+Eribulin in HER2+ MBC](https://onco.cc/trials/nct05458674/)
- key papers: [A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer](https://onco.cc/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/), [APHINITY: adjuvant pertuzumab added to trastuzumab and chemotherapy in early HER2-positive breast cancer](https://onco.cc/key-papers/paper-aphinity-nejm-2017/), [APT: adjuvant paclitaxel and trastuzumab for small, node-negative HER2-positive breast cancer](https://onco.cc/key-papers/paper-apt-tolaney-nejm-2015/), [Assessment of a HER2 scoring system for colorectal cancer: results from a validation study](https://onco.cc/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/), [Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma](https://onco.cc/key-papers/paper-fader-trastuzumab-uterine-serous-jco-2018/), [Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial (TRIUMPH)](https://onco.cc/key-papers/paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021/), [DESTINY-Gastric01: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer](https://onco.cc/key-papers/paper-destiny-gastric01-nejm-2020/), [DESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer](https://onco.cc/key-papers/paper-destiny-lung01-nejm-2022/), [DESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer](https://onco.cc/key-papers/paper-destiny-lung02-goto-jco-2023/), [DESTINY-PanTumor02: trastuzumab deruxtecan in HER2-expressing solid tumours](https://onco.cc/key-papers/paper-destiny-pantumor02-jco-2024/), [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)](https://onco.cc/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/), [HER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib](https://onco.cc/key-papers/paper-her2climb-brain-lin-jco-2020/), [HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases](https://onco.cc/key-papers/paper-her2climb-nejm-2020/), [KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment](https://onco.cc/key-papers/paper-katherine-nejm-2019/), [KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma](https://onco.cc/key-papers/paper-keynote-811-janjigian-lancet-2023/), [Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study](https://onco.cc/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/), [Phase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma](https://onco.cc/key-papers/paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019/), [Slamon 2001: adding trastuzumab to chemotherapy for HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-slamon-trastuzumab-nejm-2001/), [The self-experiment: a virologist treated her own recurrent breast cancer with two viruses she made in her own laboratory](https://onco.cc/key-papers/paper-halassy-self-experiment-ovt-vaccines-2024/), [ToGA (Bang 2010): trastuzumab with chemotherapy for HER2-positive advanced gastric cancer](https://onco.cc/key-papers/paper-toga-trastuzumab-gastric-lancet-2010/), [Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01)](https://onco.cc/key-papers/paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021/), [Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)](https://onco.cc/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/), [TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases](https://onco.cc/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/)
- terms: [Amplification](https://onco.cc/terms/amplification/), [Antibody](https://onco.cc/terms/antibody/), [Biologics Price Competition and Innovation Act 2010](https://onco.cc/terms/bpcia/), [Biosimilar](https://onco.cc/terms/biosimilar/), [Cardiotoxicity (LVEF decline, cardiomyopathy)](https://onco.cc/terms/cardiotoxicity/), [Dual HER2 blockade](https://onco.cc/terms/dual-her2-blockade/), [Epitope](https://onco.cc/terms/epitope/), [HER2-positive (IHC 3+ or ISH-amplified)](https://onco.cc/terms/her2-positive/), [Somatic mutation theory of cancer](https://onco.cc/terms/somatic-mutation-theory/), [Trastuzumab cardiotoxicity](https://onco.cc/terms/trastuzumab-cardiotoxicity/), [WHO Essential Medicines List for cancer](https://onco.cc/terms/who-essential-medicines/)
- ideas: [A public fund for trials that test less treatment](https://onco.cc/ideas/idea-tr1-public-de-escalation-trial-fund/), [A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy](https://onco.cc/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/), [An abbreviated approval path for follow-on antibodies within a validated class](https://onco.cc/ideas/idea-fund-abbreviated-pathway-me-too-biologics/), [Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials](https://onco.cc/ideas/idea-reg-biosimilar-no-efficacy-trial/), [Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy](https://onco.cc/ideas/idea-moon-cardioprotection-by-default/), [Biosimilar-first defaults and payment parity in every cancer day unit](https://onco.cc/ideas/idea-reg-biosimilar-first-default-switching/), [Can T-DXd alone cure early HER2-positive disease?](https://onco.cc/ideas/idea-tdxd-first-then-nothing/), [Fund trials that test shorter courses of the most expensive adjuvant drugs](https://onco.cc/ideas/idea-cost-shorter-course-trials/), [HER2 ADCs as standard for HER2-positive serous endometrial cancer](https://onco.cc/ideas/idea-her2-adc-serous-endometrial/), [Home infusion and local blood draws for trial drugs after the first cycles](https://onco.cc/ideas/idea-tr1-home-infusion-trial-drugs/), [Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab](https://onco.cc/ideas/idea-cost-biosimilar-default-substitution/), [Pooled international procurement of essential adult cancer medicines](https://onco.cc/ideas/idea-reg-pooled-procurement-adult-essentials/), [Pooled procurement and voluntary licensing for essential cancer medicines in low-income countries](https://onco.cc/ideas/idea-moon-pooled-procurement-licensing-pool/), [Tie WHO essential-medicines listing to a published tiered price and supply pledge](https://onco.cc/ideas/idea-acc-eml-listing-price-commitments/), [WHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator](https://onco.cc/ideas/idea-acc-biosimilar-prequalification-pool/)
- institutions: [Central Drugs Standard Control Organization](https://onco.cc/institutions/cdsco/), [Georgetown Lombardi Comprehensive Cancer Center](https://onco.cc/institutions/georgetown-lombardi/), [Hospital del Mar / Hospital del Mar Research Institute](https://onco.cc/institutions/hospital-del-mar/), [Institut Jules Bordet](https://onco.cc/institutions/institut-jules-bordet/), [Instituto Alexander Fleming](https://onco.cc/institutions/instituto-alexander-fleming/), [IRCCS Ospedale San Raffaele](https://onco.cc/institutions/san-raffaele/), [Istituto di Candiolo IRCCS (FPO)](https://onco.cc/institutions/candiolo/), [Istituto Oncologico Veneto IRCCS](https://onco.cc/institutions/iov-veneto/), [UCLA Jonsson Comprehensive Cancer Center](https://onco.cc/institutions/ucla-jonsson/)
- people: [Andrew Wardley](https://onco.cc/people/andrew-wardley/), [Barbara Bradfield](https://onco.cc/people/barbara-bradfield/), [Dennis J. Slamon](https://onco.cc/people/dennis-slamon/), [Helena Earl](https://onco.cc/people/helena-earl/), [Martine Piccart](https://onco.cc/people/martine-piccart/), [Sandra M. Swain](https://onco.cc/people/sandra-swain/), [Sara M. Tolaney](https://onco.cc/people/sara-tolaney/), [Yelena Y. Janjigian](https://onco.cc/people/yelena-janjigian/), [Yung-Jue Bang](https://onco.cc/people/bang-yung-jue/)
- bottlenecks: [Wrong doses](https://onco.cc/bottlenecks/b-dose-optimisation/)
- pathways: [Breast cancer (KEGG map)](https://onco.cc/pathways/breast-cancer-signalling/), [Drivers, passengers & the two-hit model](https://onco.cc/pathways/oncogene-activation-two-hit/), [Endometrial cancer (KEGG map)](https://onco.cc/pathways/endometrial-cancer-signalling/), [Gastric cancer (KEGG map)](https://onco.cc/pathways/gastric-cancer-signalling/), [NK-cell recognition: missing self & stress ligands](https://onco.cc/pathways/nk-cell-recognition/), [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/)
- drugs: [HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)](https://onco.cc/drugs/her2-testing-assays/)
- roadmaps: [Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall](https://onco.cc/roadmaps/targeted-therapy-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/trastuzumab.json